Clinical Trials Insight: 700028805
Latest Information Update: 13 Apr 2023
At a glance
- Drugs IMO 2055 (Primary) ; Bevacizumab; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Aceragen; Idera Pharmaceuticals
- 14 Dec 2007 Status changed from initiated to recruiting according to Idera Pharmaceuticals media release.
- 26 Nov 2007 New trial record.